Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7TD3

Sphingosine-1-phosphate receptor 1-Gi complex bound to S1P

Summary for 7TD3
Entry DOI10.2210/pdb7td3/pdb
EMDB information25822
DescriptorGuanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1, Guanine nucleotide-binding protein G(i) subunit alpha-1, Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2, ... (6 entities in total)
Functional Keywordsgpcr, complex, lipid, membrane protein
Biological sourceBos taurus (cattle)
More
Total number of polymer chains4
Total formula weight132964.49
Authors
Liu, S.,Paknejad, N.,Zhu, L.,Kihara, Y.,Ray, D.,Chun, J.,Liu, W.,Hite, R.K.,Huang, X.Y. (deposition date: 2021-12-30, release date: 2022-02-09, Last modification date: 2024-10-09)
Primary citationLiu, S.,Paknejad, N.,Zhu, L.,Kihara, Y.,Ray, M.,Chun, J.,Liu, W.,Hite, R.K.,Huang, X.Y.
Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
Nat Commun, 13:731-731, 2022
Cited by
PubMed Abstract: Lysophospholipids are bioactive lipids and can signal through G-protein-coupled receptors (GPCRs). The best studied lysophospholipids are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). The mechanisms of lysophospholipid recognition by an active GPCR, and the activations of lysophospholipid GPCR-G-protein complexes remain unclear. Here we report single-particle cryo-EM structures of human S1P receptor 1 (S1P) and heterotrimeric G complexes formed with bound S1P or the multiple sclerosis (MS) treatment drug Siponimod, as well as human LPA receptor 1 (LPA) and G complexes in the presence of LPA. Our structural and functional data provide insights into how LPA and S1P adopt different conformations to interact with their cognate GPCRs, the selectivity of the homologous lipid GPCRs for S1P versus LPA, and the different activation mechanisms of these GPCRs by LPA and S1P. Our studies also reveal specific optimization strategies to improve the MS-treating S1P-targeting drugs.
PubMed: 35136060
DOI: 10.1038/s41467-022-28417-2
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (3 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon